 Connection
Cindy O'Bryant to Retrospective Studies
This is a "connection" page, showing publications Cindy O'Bryant has written about Retrospective Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.096 |
|
|
|
-
Laird CM, Glode AE, Schwarz K, Lam ET, O'Bryant CL. Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center. J Oncol Pharm Pract. 2020 Sep; 26(6):1369-1373.
Score: 0.043
-
Gibson K, O'Bryant CL. Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors. J Oncol Pharm Pract. 2008 Sep; 14(3):139-45.
Score: 0.020
-
Chen NC, Zemplenyi AT, Adamson B, Kaizer AM, O'Bryant CL, McQueen RB, Anderson KE. Using Regression Discontinuity in Time to Strengthen Real-World Evidence: A Case Study in Lung Cancer. Med Decis Making. 2026 Jul; 46(5):601-623.
Score: 0.017
-
Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant C, Bowles DW, George B, Wen X, Aleksunes LM, Joy MS. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. Int J Mol Sci. 2017 Jun 22; 18(7).
Score: 0.009
-
Thompson LA, Saseen JJ, O'Bryant CL, Allen RR, Nair KV. Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors. J Oncol Pharm Pract. 2015 Aug; 21(4):258-67.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|